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Since the advent of highly active anti-retroviral therapy, HIV-related mortality has decreased
dramatically. As a consequence, patients are living longer, and HIV infection is becoming a
chronic disease. Patients and caretakers have to deal with chronic complications of infec-
tion and treatment, such as cardiovascular diseases, which now represent an important
health issue, even in the pediatric population. Prevalence of pulmonary arterial hypertension
(PAH) in the adult HIV population is around 0.4–0.6%, which is around 1000- to 2500-fold
more prevalent than in the general population. In recent adult PAH registries, HIV has
been identified as the fourth cause of PAH, accounting for approximately 6–7% of cases.
Therefore, regular screening is recommended in HIV-infected adults by many experts. If
HIV-associated PAH is mainly reported in HIV-infected adults, pediatric cases have also
been, albeit rarely, described. This scarcity may be due to a very low PAH prevalence, or
due to the lack of systematic cardiovascular screening in pediatric patients. As PAH may
manifest only years or decades after infection, a systematic screening should perhaps
also be recommended to HIV-infected children. In this context, we retrospectively looked
for PAH screening in children included in our national Swiss Mother and Child HIV cohort
study. A questionnaire was sent to all pediatric infectious disease specialists taking care of
HIV-infected children in the cohort.The questions tried to identify symptoms suggestive of
cardiovascular risk factors and asked which screening test was performed. In the 71 HIV-
infected children for which we obtained an answer, no child was known for PAH. However,
only two had been screened for PAH, and the diagnosis was not confirmed. In conclu-
sion, PAH in HIV-infected children is possibly underestimated due to lack of screening.
Systematic echocardiographic evaluation should be performed in HIV-infected children.
Keywords: human immunodeficiency virus, pediatrics, pulmonary artery hypertension, screening, survey
REVIEW
INTRODUCTION
WHO estimated in 2010 that 34 millions of humans were infected
with HIV, 10% being younger than 15 years old (1). In children,
infection mainly happens through transmission between mother
and child during the pre-, peri-, or postnatal period (through
breastfeeding). The risk of infection differs according to the mode
of transmission (2), and also depends on the viremia of the source
patient (3). The infected person often presents an asymptomatic
period lasting 5–10 years without treatment, depending on viremia
and CD4 T-cell count (4).
Since the advent of highly active anti-retroviral therapy
(HAART), HIV-related mortality has decreased dramatically both
in adults (5) and children (6–8). As a consequence, patients are
living longer, and HIV infection is becoming a chronic disease.
Patients and caretakers have to deal with chronic complications
of the infection and the treatment, such as cardiovascular disease,
which now represent an important health issue in this patient
population (9).
Because of the lack of randomized control studies, it is dif-
ficult to differentiate the etiological role of the virus itself from
the impact of HAART in pulmonary arterial hypertension (PAH),
as well as other cardiovascular manifestations. PAH is a seri-
ous disease of the pulmonary arteries characterized by vascular
remodeling due to dysfunctional proliferation of smooth muscle
and endothelial cells (10). It leads to an increase in pulmonary
vascular resistance and pulmonary arterial pressure (PAP). PAH
classification was updated during the World Symposium on Pul-
monary Hypertension in 2013 (11). This classification gives more
importance to pediatric PAH compared to the previous Danapoint
Classification (12).
Despite this, no systematic cardiovascular screening is usu-
ally suggested to HIV-infected children. To demonstrate this,
we sent a questionnaire to all infectious diseases special-
ists taking care of HIV-infected children in Switzerland, part
of the Swiss Mother and Child HIV (MoCHIV) cohort
study to evaluate if they look for PAH symptoms and per-
form screening procedures. We will first review HIV-related
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PAH (HIV-PAH) and second describe the results of our
questionnaire.
EPIDEMIOLOGY
Pulmonary arterial hypertension was described in HIV-infected
patients for the first time in 1987 (13). Since then, HIV has been
identified as one of the associated forms of PAH, accounting for
approximately 6–8% of cases (14–17). However, because of the
high HIV prevalence worldwide and the poor screening, HIV-PAH
may be an important unrecognized cause of PAH. Even if con-
founding factors, such as drug use and co-infection with hepatitis
C virus (HCV) have been reported (18), more than 80% of PAH
cases in the HIV population are directly related to HIV and/or its
treatment (19, 20).
Pulmonary arterial hypertension is defined as a resting PAP
>25 mmHg, associated with a pulmonary arterial occlusion pres-
sure (PAOP) ≤15 mmHg (21). HIV-PAH diagnosis can only be
confirmed once all other possible etiologies have been excluded.
Diagnosis relies on clinical symptoms, such as fatigue and
dyspnea, as well as clinical findings, such as an increase in the
pulmonary component of the second heart sound, a tricuspid
regurgitation murmur or a right fourth heart sound, and signs of
right heart failure. Chest X-rays may show cardiomegaly and pul-
monary arteries enlargement, and the electrocardiogram shows
right ventricular hypertrophy with right axis deviation. When
PAH is suspected, echocardiography is the most useful diagnostic
tool (22). Confirmation with right heart catheterization (RHC)
is the gold standard. Some authors recently proposed a diagnosis
algorithm (23, 24).
Prevalence of HIV-PAH is around 0.2–0.6% (20, 23, 25–30),
which is 1000- to 2500-fold more prevalent than in the general
population (20, 23). However, as PAH may present with very
scarce symptoms and no systematic screening is usually offered in
the HIV-infected population, these results are probably underes-
timated. Most previously mentioned studies included only symp-
tomatic patients. When all HIV-infected patients of a cohort are
included and/or when using only echocardiography without RHC
confirmation, HIV-PAH prevalence reaches 2.5–10% (18, 29, 31–
33). Compared to patients with HIV-PAH diagnosed using RHC,
mean PAP values were 20 mmHg higher when diagnosis was estab-
lished only with echocardiography, suggesting that echocardiog-
raphy overestimates PAP (22). Hsue et al. described pathological
PAP by echocardiography in 35% of their HIV-infected cohort
(14). In a recent study, HIV-PAH prevalence was 57%, but only
patients with tricuspid regurgitation were included and methods
to calculate PAP were different (34).
PHYSIOPATHOLOGY AND HISTOLOGICAL FEATURES
HIV-related PAH physiopathology is not completely understood,
is probably multifactorial, and includes genetic factors. It is
hypothesized that HIV acts as a trigger, maintaining chronic
inflammation and immune activation. Histological features,which
closely resemble those seen in idiopathic PAH, show in most cases a
pulmonary arteriopathy with so-called “plexiform lesions” associ-
ated with concentric laminar intimal fibrosis, medial hyperplasia,
and white cells. They suggest chronic inflammation (13, 19, 20,
28, 35–38). Occasionally, plexiform lesions are lacking, possibly
because it is an earlier stage of the disease (39). More rarely, throm-
botic arteriopathy of the small vessels has been described (40).
As simian immunodeficiency virus (SIV) infection of macaques
shares many characteristics with HIV infection, these animals have
been used as non-human primate model of HIV: plexiform lesions
were only recovered among macaques infected with SHIV, a viral
construct containing the HIV Nef protein in an SIV backbone,
but not among SIV alone-infected macaques (41). In contrast, in
another animal study, all SIV and SHIV macaques had elevated
PAP associated with histological changes consisting mostly of inti-
mal and medial hyperplasia. PAP values were higher in SIV and
SHIV macaques than in healthy macaques, and PAP increased as
early as 3 months after SIV infection (42).
HIV was never detected – to our knowledge – in the pulmonary
endothelial cell using different techniques, such as immunohisto-
chemistry, HIV-DNA hybridization, electron microscopy, or PCR.
The absence of virus in endothelial cells, but its presence in alve-
olar macrophages, suggests an indirect action through mediator
release rather than a direct endothelial infection (39, 43–45).
Absence of virus in endothelial cells has also been described in
SIV (46).
Endothelial dysfunction in PAH is characterized by a reduced
production of vasodilatators prostacyclin and nitric oxide (NO)
and an increased production of endothelin-1 (ET-1) (47), a
potent vasoconstrictor: its importance in idiopathic PAH pathol-
ogy has been widely studied (48). Pellicelli et al. demonstrated
increased levels of ET-1, IL-6, and TNF-alpha among HIV-PAH
patients compared to HIV-infected patients without PAH. They
also showed that plasmatic concentrations of ET-1 and IL-6 were
correlated to severity of HIV-PAH (49).
The role of viral proteins has also been studied. Despite the
absence of virus in endothelial cells, HIV envelope protein Gp120
has been shown to be toxic in vitro by inducing pulmonary
endothelial cells apoptosis and time- and dose-dependent increase
in ET-1 (50, 51). Moreover, Gp120 activates T lymphocytes (52)
and increases TNF-alpha production (51), which sustains inflam-
mation and may play a subsequent role in HIV-PAH development.
Another recent study has shown that Gp120 stimulates arter-
ial smooth muscle cells to a express tissue factor, initiating the
coagulation cascade (53). Other HIV viral proteins, such as Nef
and Tat, lead to chronic inflammation and endothelial dysfunc-
tion and may play a role in HIV-PAH pathogenesis. Nef has been
shown to increase monocyte migration, enhancing local inflam-
mation (54). Moreover, Nef was detected in lungs endothelial cells
from HIV-PAH patients, but not among healthy or idiopathic PAH
patients, suggesting that while the virus does not enter endothe-
lium, it is possible that secreted viral proteins do (41). A group
recently showed that the risk of HIV-PAH was related to the num-
ber of Nef mutations and that some polymorphisms mapped to
Nef functional domains were overrepresented among HIV-PAH
patients (55, 56).
Tat is another viral protein secreted by HIV-infected cells, which
stimulates endothelial cells, enhancing vascular permeability via
IL-6 (57). It has been suggested that Tat induces chronic inflam-
mation and endothelial dysfunction (58). Once the endothelium
is damaged, exposure of vascular smooth muscle cells to viral pro-
teins such as Tat down regulates antiangiogenic factor BMPR:
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this promotes vascular smooth muscle cells proliferation and
hypertrophy (59).
Similarly, HIV-1 proteins expression increased pulmonary vas-
cular resistance among rats exposed to chronic hypoxia compared
to wild-type rats (60).
Levels of asymmetric dimethylarginine (ADMA), an endothe-
lial NO synthase inhibitor, are increased during HIV infec-
tion because of sustained inflammation. This may contribute
to endothelial dysfunction, as ADMA levels are correlated with
PAP in HIV-infected patients (61). Platelet-derived growth fac-
tor (PDGF) can induce proliferation and migration of smooth
cells: Humbert et al. found that PDGF expression was increased
in perivascular areas of the lungs of HIV-PAH patients (43).
Similarly, increased vascular endothelial growth factor (VEGF)
expression in HIV-infected patients may alter vascular permeabil-
ity and induce endothelial cells (62). As only a small proportion of
patients develop HIV-PAH, a genetic predisposition is assumed,
such as the reported association between HIV-PAH and HLA DR6
and DR52 alleles (63). Despite being identified in 70% of familial
PAH and 20% of idiopathic PAH, no BMPR-2 mutation has been
identified among HIV-PAH patients (25).
Other factors may contribute to HIV-PAH pathophysiology.
HCV infection or drug use are independent etiologies of PAH;
however, as they are more frequent among HIV-infected patients,
they may act as confounding factors (18, 20). Cool et al. showed
the presence of human herpes virus-8 (HHV-8) in lung lesions
of patients with idiopathic PAH (64). This was not confirmed
in other studies on idiopathic PAH patients (65) and in HIV-
PAH patients, despite their immunosuppression (14, 66). Immune
restoration in mice infected by Pneumocystis jirovecii has been
shown to increase the risk of persistent PAH. However, the persis-
tence of PAH after treatment suggests that chronic inflammation
is the most important factor rather than acute infection itself (67).
CLINICAL PRESENTATION
Clinically, symptoms of HIV-PAH are similar to idiopathic PAH.
Early HIV-PAH may be misdiagnosed because of non-specific
symptoms, such as exercise intolerance, progressive dyspnea
(85%), edema (30%), and non-productive cough (19%) (19). With
the progression of the disease, signs of right ventricular dysfunc-
tion appear. Compared to idiopathic PAH, patients reported in
the literature are usually younger (mean age 33 years) (19) and
less symptomatic (35, 68). Males are proportionally more affected
(male: female ratio 1.5:1 compared to 1:1.7 in idiopathic PAH),
reflecting the prevalence of the HIV population (19). Moreover,
time between symptoms and diagnosis is generally shorter than in
idiopathic PAH: possibly a consequence of closer follow-up (25).
HIV-related PAH carries a poor prognosis: mortality is mainly
due to PAH rather than to HIV complications: PAH is therefore
a predictor of mortality by itself (20, 25, 26, 68). Initial studies
reported a median survival between 0.5 and 2.7 years (19, 27),
and only 21–46% median survival at 3 years (19, 25–27). Earlier
studies reported a faster progression (35) and a shorter survival
with HIV-PAH compared to idiopathic PAH (20, 35). This could
be explained by a more prevalent and severe ventricular systolic
dysfunction among HIV-PAH patients compared to patients with
PAH of other etiologies (69). More recent studies have shown a
slightly improved median survival with 66–86% at 3 years (17,
70, 71). As many deaths in these recent studies were unrelated
to PAH, one may suppose a decrease in HIV-PAH-related death
(71). Survival significantly decreases with an increase of NYHA
stages; therefore, a clinical marker of HIV-PAH progression (25,
68), would be crucial to identify patients in the early, scarcely
symptomatic phase of the disease.
The relationship between the severity of HIV and PAH is sub-
ject to debate. HIV-PAH occurs at all stages of HIV infection. Most
authors could not show an association between HIV-PAH and low
CD4 T cell count (19, 20, 23, 27, 28, 34, 68), even if the proportion
of patients with CD4 count <200/mm3 was higher among HIV-
PAH patients in one study (23). On the other hand, other groups
described an increased survival rate with increasing CD4 counts
(17, 25, 26).
Regarding viremia, several studies could not find an associa-
tion with HIV-PAH (23, 34, 68) but others described an increased
survival with lower viremia (17, 71). Finally, in one study, viremia
was higher among HIV-PAH patients than among HIV patients
without PAH (18). To date, there are no sufficient data to confirm
a protective role of HIV control through HAART on HIV-PAH’s
incidence and progression.
TREATMENT OF HIV-PAH
Because survival is related to NYHA stage, early diagnosis and
treatment are paramount (25, 68). There are no current validated
guidelines and HIV-PAH treatment is still controversial because
of the lack of randomized studies.
Non-specific treatment
Oxygen reduces hypoxia-induced pulmonary vasoconstriction,
whereas diuretics reduce right ventricular preload, and digoxin
increases cardiac output. Oral anticoagulation reduces the pos-
sible thrombotic component of PAH (72), but its use for HIV-
PAH is often limited due to concomitant thrombocytopenia and
hepatopathy. Calcium channel blockers (CCB) use has been dis-
appointing in adult HIV-PAH because almost all patients are not
responders to acute vasoreactivity testing, it lacks a sustained
vasodilator effect and has important side-effects (26), possibly
related to interactions with HAART (73). Given that a posi-
tive acute vasoreactivity response to CCB is more frequent in
children than adults and that there is no pediatric data con-
cerning CCB use in HIV-PAH, these medications should be con-
sidered in selected cases, but vasoreactivity is not common in
HIV-PAH.
Specific treatment
Prostacyclin analogs can be administered by IV infusion, inhala-
tion, or subcutaneously.
Epoprostenol, the intravenous form of a prostacyclin ana-
log, has been shown to induce clinical (25, 74) and hemody-
namic improvement (25, 35, 74), especially when combined to
HAART (25). Epoprostenol has been shown to increase sur-
vival (25). Its administration mode requires the use of a cen-
tral venous catheter, which is linked with risks of infection
and of misuse in drug abusers. Inhaled iloprost also showed
hemodynamic (27, 75, 76) and clinical (75, 76) improvement,
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albeit not statistically significant. Subcutaneous treprostinil
increases hemodynamic and clinical parameters (77) in HIV-
PAH patients.
Sildenafil, a phosphodiesterase inhibitor type 5, is the most fre-
quently used medication in idiopathic PAH. In HIV-PAH, its use
is limited because of its interaction with protease inhibitors (PIs),
through the 3A4 P450 cytochrome pathway (78–80). However,
in case reports of patients with HIV-PAH, it showed clinical and
hemodynamic improvement (81–83).
Bosentan, an oral dual endothelin receptor antagonist, acts by
inhibiting the potent vasoconstricting properties of endothelin.
Bosentan has been shown to induce a clinical and hemody-
namic improvement among HIV-infected patients (26, 71, 84, 85).
Some patients even normalized their hemodynamic values dur-
ing treatment (71). In 2012, Tcherakian et al. reported two cases
of sustained and completely reversible HIV-PAH with bosentan
treatment, persisting after drug discontinuation (86). Bosentan
is a moderate Cytochrome P450 3A4 and 2C9 inducer, therefore
simultaneous administration of anti-retroviral drugs should be
performed with caution (87).
A treatment algorithm was recently proposed for HIV-
PAH (88).
ROLE OF HAART IN HIV-PAH
The role of HAART in PAH is unclear. As chronic inflamma-
tion probably contributes to HIV-PAH pathophysiology, one may
suspect a beneficial effect of HAART on HIV-PAH by reducing
inflammation. In rats, PIs reverse or decrease PAH progression by
reducing remodeling and smooth muscle cell proliferation (89).
In humans, some authors showed no change in the frequency
or severity of PAH since HAART was introduced, or in patients
treated with HAART (17, 18, 23, 26), whereas others described
a decrease of PAH incidence (27, 90) associated with a decline
in HIV-PAH-related mortality (25, 27, 71). Among patients with
HIV-PAH, clinical improvement was observed, especially when
associated to PAH medications (17,85). In a similar fashion,hemo-
dynamics improved with HAART whether or not associated to
PAH medication (26, 27, 85, 91). It is possible that PIs may be the
most beneficial (27).
On the other hand, other studies have shown a delete-
rious effect of HAART on HIV-PAH, possibly secondary to
PI-induced endothelial dysfunction (92). In vitro studies have
demonstrated that anti-retrovirals, especially PIs, increased ET-
1 production, followed by endothelial and vascular smooth
muscle cell proliferation (93). Among rats, administration of
AZT and PIs was associated to endothelial dysfunction and an
increase in ET-1 production (94). In humans, some authors
describe stable HIV-PAH after HAART interruption (95), while
others describe an increased incidence with HAART com-
pared to ART (96, 97) or an accelerated HIV-PAH evolu-
tion (44). Reinsch et al. reported an increased echocardio-
graphically proven HIV-PAH prevalence among patients treated
with HAART compared to naïve patients (31). Another human
study associated ritonavir-boosted PIs and abacavir with HIV-
PAH (34).
In general, HIV-PAH prevalence has not changed significantly
since HAART was introduced. This may suggest that antiviral
drugs have a little effect on sites where the virus affects vascular
cells. However, a protective effect of HAART on survival and inci-
dence may explain a stable prevalence, as patients are now living
longer. In clinical practice, since the Opravil et al. study showing
an improvement of the pressure gradient when the patients were
treated, experts recommend to introduce HAART at the time of
HIV-PAH diagnosis, regardless of CD4 T-cell counts (26).
PEDIATRIC DATA
While HIV-PAH mainly concerns HIV-infected adults, pediatric
cases have also been described (63, 83, 98–104), the youngest
being between 1 and 2 years old (83, 102). Apart from HIV infec-
tion, few of these children also have other PAH predisposing
factors, such as hemophilia (99, 101). The youngest patient is
an HIV-infected very-low birth-weight infant, which presented
with neonatal PAH: his condition resolved with HAART treat-
ment but confounding factors, such as persistent ductus arteriosus,
prolonged mechanical ventilation, extreme prematurity, systemic
infection, and persistent pulmonary hypertension of the new-
born, may have contributed to the disease (105). The causality
is therefore uncertain. In a cohort of pediatric PAH patients in
the Netherlands, 1% of cases were infected with HIV (98). In
vertically HIV-infected children in Thailand, more than 40% pre-
sented echocardiographic criteria for HIV-PAH, but in more than
half of the cases, this could be explained by lymphoid intersti-
tial pneumonia (106). More recently, Ferrand et al. diagnosed
HIV-PAH by echocardiography in 7% of vertically infected ado-
lescents (aged 10–19 years) from Zimbabwe (107). Cunha et al.
described an echocardiographic prevalence of HIV-PAH in 4.4%
of a Brazilian children cohort younger than 13 years (108). Two
studies in Thailand and Zimbabwe including only symptomatic
HIV-infected toddlers have described an HIV-PAH prevalence of
48–75% (109, 110). The prevalence of echocardiographic HIV-
PAH among children is similar or even higher than in adult
reports using only echocardiography as a diagnostic tool. This
high prevalence among HIV-infected children in Asia, Africa,
and South America may be explained by vertical transmission. A
delayed HIV diagnosis such as described in Ferrand et al. (median
age at diagnosis 12 years) may also have contributed to the high
HIV-PAH prevalence (107). Finally, confounding factors, such as
high prevalence of parasitic diseases, chronic hepatitis B and C
infection, and high seroprevalence of HHV-8 could have played
a role.
In a recent registry study of more than 360 children in 19 coun-
tries – including Switzerland – with confirmed PAH, there was
no HIV-infected child (111). Similarly, there was no HIV-infected
patient in another registry study including more than 200 children
with PAH (112). This may be due to the fact that no systematic
screening is performed in the HIV-infected population but also to
a selection bias of both registries and their participating centers as
almost all patients were symptomatic.
WHAT IS DONE IN SWITZERLAND?
To demonstrate a correlation between HIV and PAH in HIV-
infected children, we retrospectively analyzed cardiovascular and,
in particular, PAH screening of children in the Swiss MoCHIV
cohort study.
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FIGURE 1 | Questionnaire sent to Swiss pediatric infectious diseases specialists following HIV-infected children.
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The MoCHIV Cohort Study is a merger of the former Neona-
tal HIV Study and the Swiss HIV and Pregnancy Study. Initially,
the main goal was to collect a maximum of data in children born
to HIV-infected mothers and HIV-infected children to gain epi-
demiological information and to study vertical transmission and
natural history of disease. In 1998, a merged project was built
named The Swiss MoCHIV Study. In 2004, a permanent link was
established between the Swiss HIV Cohort Study (SHCS) and
MoCHIV. Thus, longitudinal data in women included in both
cohorts became available for research, making MoCHIV a very
unique mother–child cohort. All mothers and children are given a
cohort number, which is then used to collect data in both cohorts
anonymously. Women and children are followed according to
good clinical practices, as defined by the respective guidelines for
adults, pregnant women, and children. These have been regularly
adjusted according to growing knowledge.
It is estimated that approximately 75% of HIV-infected chil-
dren living in Switzerland are part of MoCHIV. All Swiss pediatric
infectious disease experts following HIV-infected children in the
cohort received a person-specific questionnaire. The questions
concerned symptoms suggestive of PAH and which cardiovascular
screening was performed. In addition, questions concerning HIV
status (CD4 T-cell count, viremia, HAART treatment or not) were
recorded (Figure 1).
Among the 83 children currently included in the MoCHIV
cohort study, the questionnaire was retrieved for 71 (86%) chil-
dren. As suspected, no child of the MoCHIV cohort was known
for PAH. Only two children (3%) had been screened for PAH,
one because of thoracic pain and one because of dizziness, but
diagnosis was not confirmed. Echocardiographic studies have
reported higher prevalence of PAH (106–110). It is therefore pos-
sible that HIV-PAH is under-diagnosed in Switzerland as well
because systematic screening is not performed. Only symptomatic
cases would be (or will be) detected. Alternatively, it is also possible
that other cofactors are involved and explain the higher prevalence
in other countries.
CONCLUSION
Increased PAH risk in HIV-infected children, due to HIV infec-
tion and/or anti-retroviral treatment, creates new challenges and
has serious implications for the quality of life and the survival
of this population. However, despite a clearly increased risk, PAH
detection is neglected in HIV-infected children. The true impact
of PAH can only be appreciated after years or decades because
of its silent and slow progression. Survival among HIV-infected
children will probably continue to increase with more potent treat-
ment options. As demonstrated in several studies, the prevalence
of echocardiographic signs of increased PAP despite being below
PAH definition level is more frequent than expected, even in chil-
dren. Therefore, a systematic PAH screening should be proposed
in this at-risk population (113–117). An echocardiography should
be performed in all HIV-infected children at least once. How-
ever, a regular echocardiographic follow-up would be even more
helpful, despite its cost, because there is a better outcome when
diagnosis is early. RHC should be offered to all patients with abnor-
mal echocardiographic findings. This has been successfully done
in adult patients with sickle cell disease or scleroderma, another
pathology associated with PAH (118, 119). Moreover, because only
a proportion of HIV-infected patients develop HIV-PAH, finding
biomarkers predicting HIV-PAH would be essential for the future.
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